NeoStem, Inc. has entered agreements with the University of California, San Francisco and the labs of Jeffrey Bluestone, Ph.D., and Qizhi Tang, Ph.D., for the development of human Regulatory T cells (Tregs) for the treatment of type 1 diabetes, steroid resistant asthma, and organ transplant rejection.   NeoStem will manufacture a Treg product for a Phase II trial to treat patients newly diagnosed with type 1 diabetes and will collaborate with Dr. Bluestone on allo-specific Tregs for organ transp...